Entering text into the input field will update the search result below

Exelixis initiated Outperform at BMO; says concerns over generics are overblown

Jun. 24, 2022 1:16 PM ETExelixis, Inc. (EXEL) StockBy: Dulan Lokuwithana, SA News Editor3 Comments

Wall street sign in New York with New York Stock Exchange background

naphtalina/iStock via Getty Images

BMO Capital Markets has initiated the coverage of oncology-focused biotech Exelixis (NASDAQ:EXEL) with an Outperform recommendation arguing that the company shares are trading below a worst-case scenario implied for a potential entry of generics. The

Recommended For You

About EXEL Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
EXEL--
Exelixis, Inc.